1 / 21

Extreme Drug Resistant TB and the Work Place

Extreme Drug Resistant TB and the Work Place. Dr Jennifer Coetzee Ampath. Outline. The “ABC” of TB drug resistance Current anti-TB drugs available What is MDR? What is XDR? How does TB drug resistance develop? Epidemiology of XDR TB XDR TB in the work place?

walter
Télécharger la présentation

Extreme Drug Resistant TB and the Work Place

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Extreme Drug Resistant TB and the Work Place Dr Jennifer Coetzee Ampath

  2. Outline • The “ABC” of TB drug resistance • Current anti-TB drugs available • What is MDR? • What is XDR? • How does TB drug resistance develop? • Epidemiology of XDR TB • XDR TB in the work place? • Prevention and management of TB transmission in the occupational setting

  3. 1st Line Drugs: INH Rifampicin PZA Ethambutol Streptomycin 2nd Line Drugs Capreomycin Kanamycin Ethionamide PAS Cycloserine Quinolones Thiacetazone Anti TB Drugs Currently Available

  4. The ABC of TB Drug Resistance • MDR TB: Resistance to INH and Rifampicin • XDR TB: MDR TB that is also resistant to quinolones (e.g. ciprofloxacin) and one other of 2nd line injectable drug • Thus Extreme Drug resistance • Laboratory diagnosis based on susceptibility testing • Cure rate for MDR TB +/- 50% • XDR TB 64% more likely to die than if MDR TB

  5. How does TB drug resistance develop? • Spontaneous and random mutations in the bacterial • chromosome: • INH - 1 X 106 organisms • Rif - 1 x 108 • EMB - 1 x 106 • Strep - 1 x 105 • Probability of spontaneous mutants being simulta- neously resistant to 2 or more drugs is product of individual frequencies… • INH + Rif = 106 + 108 = 1014

  6. MDR: Global Perspective • 50 million people infected worldwide • Low prevalence of MDR: • well functioning TBCP with DOTS, low prevalence of TB, resource rich • High prevalence of MDR TB: • high TB rates, poor countries, limited medication available • MDR rates estimated to be 3 - 4% • Primary MDR: 1 - 3% • Acquired: 7 - 17%

  7. Implications of MDR TB • 100 X more expensive to treat • Duration of Rx up to 24 months • Patient hospitalised for 4 - 6 months • Extensive laboratory monitoring required • Side effects of 2nd line drugs significant • Inconvenient routes of administration • >30% default rate • Treatment failure > 10% if optimally Mx • Mortality rate: • 30 - 40% if HIV uninfected • 70 - 80% if HIV infected

  8. XDR TB • Hot off the press • Term coined in March 2006 • Report published in MMWR 24/03/06 • 350 cases worldwide between 2000 and 2004 • Primarily in South Korea, Eastern Europe and western Asia • 74 cases in USA

  9. Current Situation XDR • USA: 4% of MDR cases meet criteria for XDR • Latvia: 19% of MDR cases considered XDR • Australia, Belgium, Canada, France, Germany, Ireland, Portugal, Spain, Britain: • XDR TB increased from 3% of drug resistant cases to 11% (2000 to 2004) • Pandemic threat!

  10. RSA: The Tugela Ferry Event • In Tugela Ferry HIV/TB co-infected patients, respon- ding to ARV but not to ATT, were identified early 2005 • This prompted culture and susceptibility testing • Infection with highly resistant M.tuberculosis

  11. South African Situation (Tugela Ferry) Surveillance at District Hospital: 1428 Patients with sputum sent 921 Culture-Negative 475 (34%) Culture-Positive for M.tb Lancet 2006, 368:1575-1580

  12. 475 patients Culture-Positive for M.tb 290 Susceptible or Resistant but not MDR 185 (39%) Resistant to Isoniazid & Rifampin (MDR TB) 30 (6%) Resistant to all tested drugs (XDR TB) Prof. W. Sturm

  13. Overall Data for the Area • 52 of 53 people with XDR TB died • 44 were co-infected with HIV • Average survival was 16 days after sputum collection • 55% of the patients were primary XDR! • At least 2 HCWs were infected, died. A further 4 were suspected to have contracted XDR TB • Strain resistant to all 7 anti-TB drugs available in SA • Impact of 5.5 million people infected with HIV/AIDS

  14. Susceptibility Pattern • Isoniazide R • Rifampicin R • Pyrazinamide R • Ethambutol R • Streptomycin R • Kanamycin/amikacin R • Ciprofloxacin/ofloxacin R • Ethionamide S • Cycloserine ? • Capreomycin S • PAS ?

  15. XDR TB and the Work Place • Health care workers from KZN only published proven transmission of XDR TB to have occurred to date • Recent case of patient with XDR TB on aero- plane in US • Outbreaks of MDR TB has been well described • No evidence to suggest that MDR or XDR TB is more easily transmitted than drug susceptible TB

  16. Principles of TB Transmission • Inhalation of microscopic, aerosolised particles containing TB bacilli • Vast majority: particles elaborated by coughing, sneezing or singing • Alveolar deposition thought to be essential • Tiny enough to drift with inspired air rather than impact on mucous membranes • Droplet nuclei of 0.5-5 µm usually vectors of infection • Patients with extensive pulmonary TB pose greatest risk • Study form Alabama, gradient of skin-test reactivity of contacts: • HHCs to smear (+) cases: 46% • Non-HHCs to smear (+) cases: 34% • HHCs to smear (-), culture (+) cases: 28% • Non-HHCs to smear (-), culture (+) cases: 24%

  17. Environmental Factors That Increase the Risk of Transmission of TB • Exposure to TB in small, enclosed spaces • Inadequate local or general ventilation that results in insufficient dilution or removal of infectious nuclei • Recirculation of air containing infectious droplet nuclei • Inadequate cleaning and disinfection of medical equipment • Improper procedure for handling specimens

  18. Risk for Health-Care Associated Transmission of TB • Transmission and outbreaks well described • Magnitude of risk varies by: • Setting • Occupational group • Prevalence of TB in the community • Patient population • Effectiveness of TB infection-control measures

  19. Outbreaks in Health-Care Settings • Multiple outbreaks involved transmission of MDR TB strains to both patients and HCWs • Majority of patients and HCWs were HIV infected • Also outbreaks described in outpatient settings • Factors contributing to outbreaks: • Delayed diagnosis of TB disease • Delayed initiation and inadequate airborne precautions • Inadequate precautions for cough-inducing and aerosol-generating procedures • Lack of adequate respiratory protection

  20. Principles of Management of TB Contacts • Earliest possible identification of index cases • Rapid laboratory detection of MDR TB if indicated • Duration / time-line of exposure often unknown • Baseline CXR, symptom screening • Diagnosis of latent TB infection • Role of blood assays, incl. TB Spot, Quantiferon Gold • Skin testing? • Counseling, HIV testing imperative • Risk of reactivation disease • Treatment of latent TB infection • If exposed to MDR/XDR TB, to be referred to infectious disease specialist. Optimal therapy unknown.

  21. Conclusion “After 25 years working in TB treatment, I’m extremely concerned - we see very little progress, and there seems to be complacency in general about TB” Dr Karin Weyer, August 2006

More Related